Is time‐restricted eating (8/16) beneficial for body weight and metabolism of obese and overweight adults? A systematic review and meta‐analysis of randomized controlled trials

Time‐restricted eating (TRE) is a new therapeutic strategy for the management of weight loss and dysmetabolic diseases. At present, TRE (8/16, 8 h eating:16 h fasting) is the most common form of TRE. Therefore, this meta‐analysis included randomized controlled trials (RCTs) on TRE (8/16) in overweight and obese adults to determine its impact on body weight and metabolism. Articles reviewed from PubMed, Ovid MEDLINE, Embase, and Cochrane Central Register for the relevant RCTs that compared TRE (8/16) to non‐TRE in overweight and obese adults. Eight RCTs were included in this meta‐analysis. Participants following TRE (8/16) showed significant body weight reduction (mean difference [MD]: −1.48 kg, 95% confidence interval [CI]: −2.53 to −0.44) and fat mass reduction (MD: −1.09 kg, 95% CI: −1.55 to −0.63). There was no significant difference in lean mass change with TRE intervention (MD: −0.48 kg, 95% CI: −1.02 to 0.05, p = .08, I (2) = 41%). The energy restriction and early TRE (eTRE) subgroups resulted in greater weight loss. TRE (8/16) showed beneficial effects on the homeostatic model assessment of insulin resistance (HOMA‐IR, MD: −0.32, 95% CI: −0.59 to −0.06), but had no significant effect on other parameters of glucose metabolism and lipid profiles. In conclusion, TRE (8/16), especially eTRE, or in combination with caloric intake restriction, is a potential therapeutic strategy for weight control in overweight and obese adults. TRE (8/16) also reduced HOMA‐IR; therefore, it may have a positive effect on glucose metabolism.